Surface modification of pancreatic islets using heparin-DOPA conjugate and anti-CD154 mAb for the prolonged survival of intrahepatic transplanted islets in a xenograft model

Biomaterials

Volumn 33, Issue 1, 2012, Pages 295-303

  Jung, Yoon Suk ^a   Jeong, Jee Heon ^a   Yook, Simmyung ^a   Im, Bok Hyeon ^a   Seo, Jinwon ^a   Hong, Sung Woo ^c   Park, Jun Beom ^c   Yang, Victor C ^c,d   Lee, Dong Yun ^b   Byun, Youngro ^a,c  

^a Seoul National University   (South Korea)

^b Hanyang University   (South Korea)

^c Seoul National University   (South Korea)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti CD154 monoclonal antibody; DOPA; Heparin; Islet transplantation; Surface modification

Indexed keywords

COMBINATION METHOD; COMBINED EFFECT; DOPA; HEPARIN; IMMUNOPROTECTION; IMMUNOSUPPRESSIVE DRUGS; INFLAMMATORY REACTION; ISLET TRANSPLANTATION; LOW DOSE; NORMOGLYCEMIA; PANCREATIC ISLET; SURFACE COVERAGES; SURVIVAL RATE; SURVIVAL TIME;

AMINO ACIDS; DRUG DOSAGE; GRAFTING (CHEMICAL); MONOCLONAL ANTIBODIES; SURFACE TREATMENT;

POLYSACCHARIDES;

CD40 LIGAND MONOCLONAL ANTIBODY; DOPA; HEPARIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; SURVIVAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOCOMPATIBLE MATERIALS; CD40 LIGAND; CELL SURVIVAL; DIHYDROXYPHENYLALANINE; GRAFT SURVIVAL; HEPARIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED C57BL; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 82855175136     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.051     Document Type: Article

References (28)

1. Shapiro A.M.J., Lakey J.R.T., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New Engl J Med 2000, 343:230-238.
2. Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355:1318-1330.
3. Ryan E.A., Lakey J.R., Rajotte R.V., Korbutt G.S., Kin T., Imes S., et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001, 50:710-719.
4. Bennet W., Sundberg B., Groth C.G., Brendel M.D., Brandhorst D., Brandhorst H., et al. Incompatibility between human blood and isolated islets of langerhans - a finding with implications for clinical intraportal islet transplantation?. Diabetes 1999, 48:1907-1914.
5. Pierson R.N., Dorling A., Ayares D., Rees M.A., Seebach J.D., Fishman J.A., et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009, 16:263-280.
6. Mirenda V., Golshayan D., Read J., Berton I., Warrens A.N., Dorling A., et al. Achieving permanent survival of islet xenografts by independent manipulation of direct and indirect T-cell responses. Diabetes 2005, 54:1048-1055.
7. Smith R.M., Mandel T.E. Pancreatic islet xenotransplantation: the potential for tolerance induction. Immunol Today 2000, 21:42-48.
8. Wilson J.T., Chaikof E.L. Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics. J Diabetes Sci Technol 2008, 2:746-759.
9. Moberg L., Johansson H., Lukinius A., Berne C., Foss A., Kallen R., et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
10. Ozmen L., Ekdahl K.N., Elgue G., Larsson R., Korsgren O., Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002, 51:1779-1784.
11. van der Windt D.J., Bottino R., Casu A., Campanile N., Cooper D.K. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 2007, 14:288-297.
12. Johansson H., Goto M., Dufrane D., Siegbahn A., Elgue G., Gianello P., et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006, 6:305-312.
13. Berman D.M., Cabrera O., Kenyon N.M., Miller J., Tam S.H., Khandekar V.S., et al. Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation 2007, 84:308-315.
14. Shapiro A.M., Lakey J.R., Rajotte R.V., Warnock G.L., Friedlich M.S., Jewell L.D., et al. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995, 59:1060-1063.
15. Walsh T.J., Eggleston J.C., Cameron J.L. Portal hypertension, hepatic infarction, and liver failure complicating pancreatic islet autotransplantation. Surgery 1982, 91:485-487.
16. Lee D.Y., Park S.J., Nam J.H., Byun Y. A combination therapy of PEGylation and immunosuppressive agent for successful islet transplantation. J Control Release 2006, 110:290-295.
17. Yun Lee D., Hee Nam J., Byun Y. Functional and histological evaluation of transplanted pancreatic islets immunoprotected by PEGylation and cyclosporine for 1 year. Biomaterials 2007, 28:1957-1966.
18. Lee D.Y., Yang K., Lee S., Chae S.Y., Kim K.W., Lee M.K., et al. Optimization of monomethoxy-polyethylene glycol grafting on the pancreatic islet capsules. J Biomed Mater Res 2002, 62:372-377.
19. Cabric S., Sanchez J., Lundgren T., Foss A., Felldin M., Kallen R., et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007, 56:2008-2015.
20. Lee H., Scherer N.F., Messersmith P.B. Single-molecule mechanics of mussel adhesion. Proc Natl Acad Sci U S A 2006, 103:12999-13003.
21. Sun I.C., Eun D.K., Na J.H., Lee S., Kim I.J., Youn I.C., et al. Heparin-coated gold nanoparticles for liver-specific CT imaging. Chem-Eur J 2009, 15:13341-13347.
22. Guvendiren M., Brass D.A., Messersmith P.B., Shull K.R. Adhesion of DOPA-functionalized model membranes to hard and soft surfaces. J Adhes 2009, 85:631-645.
23. Lee H., Dellatore S.M., Miller W.M., Messersmith P.B. Mussel-inspired surface chemistry for multifunctional coatings. Science 2007, 318:426-430.
24. Lacy P.E., Kostianovsky M. Method for the isolation of intact islets of langerhans from the rat pancreas. Diabetes 1967, 16:35-39.
25. Waite J.H., Tanzer M.L. Polyphenolic Substance of Mytilus edulis: novel adhesive containing L-DOPA and hydroxyproline. Science 1981, 212:1038-1040.
26. Yu M.E., Hwang J.Y., Deming T.J. Role of L-3,4-dihydroxyphenylalanine in mussel adhesive proteins. J Am Chem Soc 1999, 121:5825-5826.
27. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004, 103:1229-1236.
28. Kanmaz T., Fechner J.J., Torrealba J., Kim H.T., Dong Y., Oberley T.D., et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004, 77:914-920.